My watch list
my.bionity.com  
Login  

149 Current news about the topic melanoma

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Therapeutic Vaccines for Cancer Treatment

VPM organizes clinical development - Initial focus on prostate cancer

21-Apr-2004

Braunschweig/Munich/New York. Vakzine Projekt Management GmbH (VPM), Braunschweig, Germany, has obtained from Memorial Sloan-Kettering Cancer Center a worldwide exclusive license for several patents covering a range of recombinant cell lines. These cell lines have a high potential to ...

more

MedImmune and Cerus to Present Data on Novel Vaccine Technology's Potential to Help Treat and Prevent Cancers

30-Mar-2004

Gaitersburg. MedImmune, Inc. and Cerus Corporation announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors. These results will be presented at the 95th Annual Meeting of the American Association for Cancer ...

more

Munich Biotech Reports Additional Positive Data From MBT- 0206 Phase I Trial

26-Mar-2004

Munich Biotech AG has announced details of results presented during a recent congress of clinical investigators, reporting on results of Phase I trials of MBT-0206 in cancer patients. New results have indicated that patients continuing with MBT-0206 beyond the trial period on compassionate ...

more

Astex, The Wellcome Trust, The Institute of Cancer Research and Cancer Research Technology announce major cancer drug discovery

23-Mar-2004

Astex Technology, the fragment-based drug discovery company, together with The Wellcome Trust, the Institute of Cancer Research and Cancer Research Technology announced an exclusive collaboration relating to the discovery of novel drugs against the cancer target BRAF. BRAF was first identified ...

more

Generex Reports on Novel Mechanism for Immunotherapy Cure of Prostate Cancer

Scientists Identify Immunoregulatory Mechanism to Fight Cancer and Infectious Diseases

13-Jan-2004

TORONTO, -- Generex Biotechnology Corporation announced the recent presentation of a poster at the Keystone Symposium, "Rational Design of Vaccines and Immunotherapies" in Colorado, on a novel cancer vaccination method developed by scientists and collaborators at its Antigen Express subsidiary. ...

more

Array BioPharma and AstraZeneca Announce Oncology Collaboration

Phase I Clinical Trial on Array's Lead MEK Inhibitor Targeted for 2004

19-Dec-2003

Array BioPharma and AstraZeneca announced a licensing and collaboration agreement to develop Array's MEK program in the field of oncology. The program includes the clinical development candidate (ARRY-142886) and related intellectual property. Under the agreement, Array will receive an upfront ...

more

Generex Biotechnology announces $444,000 phase I NIH SBIR award for melanoma peptide vaccine

17-Sep-2003

Generex Biotechnology Corporation announced that the National Cancer Institute has awarded a Small Business Innovative Research (SBIR) grant to support development of a novel vaccine for T- helper cell-stimulating peptide vaccines to treat malignant melanoma. The research will be carried out by ...

more

Epimmune and Anosys announce plans to merge

17-Feb-2003

Epimmune Inc., and Anosys, Inc. announced that they have preliminarily agreed to merge their operations to create a combined company focused on the field of immunotherapeutics and products for the treatment of cancer and infectious diseases. The all-stock transaction is subject to the parties ...

more

Abbott Laboratories To Acquire A Leading Genomic Disease Management Company

25-Oct-2001

Abbott Park, and Downers Grove, Illinois, October 24, 2001 — Abbott Laboratories and Vysis, Inc. announced that the companies have entered into a definitive agreement for Abbott to acquire Vysis, a leading genomic disease management company that develops and markets clinical laboratory products, ...

more

Page 15 From 15
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE